Activate Now
 
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Acupuncture used in clinical settings reduced symptoms of menopause

Benefits of Coconut Oil Are Undeniable

How Awesome Is Ashwagandha?

SURVEY RESULTS: Should Opioids Be Restricted for Chronic Illness?

CoQ10 supplementation associated with lower pro-inflammatory factors in randomized trial

Clinical trial demonstrates success of low FODMAP diet

Research Demonstrates Superiority of Krill Oil Compared to Fish Oil

Vitamin nicotinamide riboside protects mice from diabetes complications

What’s so Remarkable About Rosemary?

Vitamin-mineral supplement prevents brain cell loss in recent research

 
Print Page
Email Article

ViroPharma Drug Gets a 2nd Shot at Approval: Pleconaril

  [ 71 votes ]   [ Discuss This Article ]
www.ProHealth.com • January 5, 2004


INDUSTRY WRAPUPS

Biotech

John George

Exton-based ViroPharma Inc., which shelved its experimental treatment for the common cold after it was rejected by Food and Drug Administration early last year, has entered into a new deal for Pleconaril with Schering-Plough Corp. of Kenilworth, N.J.

The two companies entered into an option agreement that could result in Schering-Plough receiving a license for ViroPharma's intranasal formulation of its antiviral compound Pleconaril as a treatment of the common cold in the United States and Canada.

Under terms of the agreement, Schering-Plough will pay ViroPharma an up-front option fee of $3 million. ViroPharma will then conduct a series of clinical studies designed to evaluate the antiviral activity, safety and other performance characteristics of the intranasal Pleconaril formulation.

Results from the studies are expected to be available in mid-2004.

Based on its assessment of the product's performance in the characterization studies, Schering-Plough will then have the option to trigger a full license agreement with ViroPharma, under which it would assume responsibility for all future development and commercialization of intranasal Pleconaril domestically and in Canada.

If Schering-Plough exercises its option, ViroPharma will receive an initial license fee of $10 million and Schering-Plough will buy ViroPharma's existing inventory of bulk drug substance for Pleconaril for an additional undisclosed fee. ViroPharma also would be eligible to receive additional milestone payments if it achieves certain targeted, but unspecified, events as well as royalties on Schering-Plough's sales of intranasal Pleconaril in the licensed territories.

"We are delighted that we've entered into this agreement with Schering-Plough," said Mark McKinlay, ViroPharma's vice president of research and development. "We hope to demonstrate that this formulation can deliver significantly more drug to the site of active common cold infections than the oral formulation, while limiting its systemic exposure and minimizing the risk of drug interactions."

The FDA rejected a tablet formulation of Pleconaril in March 2002 citing safety concerns tied to the drug's potential adverse interactions with other drugs, such as birth control pills and AIDS medicine. An FDA advisory committee also said it was concerned the widespread use of Pleconaril had the potential to yield new drug-resistant viruses.

Source: Philadelphia Business Journal.



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Energy NADH™ 12.5mg FibroSleep™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
All Natural Deodorants

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value
Milk Thistle: Trusted Support for Health & Healing in a Toxic World Milk Thistle: Trusted Support for Health & Healing in a Toxic World
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH
How to Jump-start and Sustain Energy Production in CFS How to Jump-start and Sustain Energy Production in CFS

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler

· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map